<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-014-0541-9</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections
               due to ceftriaxone non-susceptible 
               <i>Escherichia coli</i> and 
               <i>Klebsiella</i> spp (the MERINO trial): study protocol for a randomised controlled trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Harris</span>
               <span tagx="mnm">NA</span>
               <span tagx="fnm">Patrick</span>
               <span tagx="insr"></span>
               <a href="p.harris@uq.edu.au">p.harris@uq.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Peleg</span>
               <span tagx="mi">Y</span>
               <span tagx="fnm">Anton</span>
               <span tagx="insr"></span>
               <a href="anton.peleg@monash.edu">anton.peleg@monash.edu</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Iredell</span>
               <span tagx="fnm">Jon</span>
               <span tagx="insr"></span>
               <a href="jon.iredell@swahs.health.nsw.gov.au">jon.iredell@swahs.health.nsw.gov.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Ingram</span>
               <span tagx="mi">R</span>
               <span tagx="fnm">Paul</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="paul.ingram@health.wa.gov.au">paul.ingram@health.wa.gov.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Miyakis</span>
               <span tagx="fnm">Spiros</span>
               <span tagx="insr"></span>
               <a href="spiros_miyakis@uow.edu.au">spiros_miyakis@uow.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Stewardson</span>
               <span tagx="mi">J</span>
               <span tagx="fnm">Andrew</span>
               <span tagx="insr"></span>
               <a href="andrew.stewardson@gmail.com">andrew.stewardson@gmail.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Rogers</span>
               <span tagx="mi">A</span>
               <span tagx="fnm">Benjamin</span>
               <span tagx="insr"></span>
               <a href="b.rogers1@uq.edu.au">b.rogers1@uq.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">McBryde</span>
               <span tagx="mi">S</span>
               <span tagx="fnm">Emma</span>
               <span tagx="insr"></span>
               <a href="emma.mcbryde@burnet.edu.au">emma.mcbryde@burnet.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Roberts</span>
               <span tagx="mi">A</span>
               <span tagx="fnm">Jason</span>
               <span tagx="insr"></span>
               <a href="j.roberts2@uq.edu.au">j.roberts2@uq.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Lipman</span>
               <span tagx="fnm">Jeff</span>
               <span tagx="insr"></span>
               <a href="j.lipman@uq.edu.au">j.lipman@uq.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Athan</span>
               <span tagx="fnm">Eugene</span>
               <span tagx="insr"></span>
               <a href="eugene@barwonhealth.org.au">eugene@barwonhealth.org.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Paul</span>
               <span tagx="mi">K</span>
               <span tagx="fnm">Sanjoy</span>
               <span tagx="insr"></span>
               <a href="Sanjoy.Paul@qimrberghofer.edu.au">Sanjoy.Paul@qimrberghofer.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Baker</span>
               <span tagx="fnm">Peter</span>
               <span tagx="insr"></span>
               <a href="p.baker1@uq.edu.au">p.baker1@uq.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Harris-Brown</span>
               <span tagx="fnm">Tiffany</span>
               <span tagx="insr"></span>
               <a href="t.brown3@uq.edu.au">t.brown3@uq.edu.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Paterson</span>
               <span tagx="mi">L</span>
               <span tagx="fnm">David</span>
               <span tagx="insr"></span>
               <a href="david.antibiotics@gmail.com">david.antibiotics@gmail.com</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>University of Queensland Centre for Clinical Research, Building 71/918 Royal Brisbane
                  &amp; Women’s Hospital Campus, Herston, Brisbane, 4029, QLD, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Infectious Diseases, The Alfred Hospital, Melbourne, VIC, Australia</p>
            </li>
            <li tagx="ins">
               <p>Westmead Millenium Institute for Medical Research, Westmead Hospital, Sydney, NSW,
                  Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA,
                  Australia
               </p>
            </li>
            <li tagx="ins">
               <p>School of Pathology and Laboratory Medicine, University of Western Australia, Crawley,
                  WA, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Infectious Diseases, School of Medicine, University of Wollongong and
                  The Wollongong Hospital, Wollongong, NSW, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Infectious Diseases, Austin Health, Melbourne, VIC, Australia</p>
            </li>
            <li tagx="ins">
               <p>Monash Infectious Disease, Monash Health, Clayton, VIC, Australia</p>
            </li>
            <li tagx="ins">
               <p>Victorian Infectious Diseases Unit, Royal Melbourne Hospital, Melbourne, VIC, Australia</p>
            </li>
            <li tagx="ins">
               <p>Burns Trauma and Critical Care Research Centre, The University of Queensland, Brisbane,
                  QLD, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Infectious Disease, Barwon Health, Deakin University, Geelong, VIC,
                  Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Clinical Trials &amp; Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane,
                  QLD, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Queensland Clinical Trials and Biostatistics Centre, University of Queensland, Brisbane,
                  QLD, Australia
               </p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">24</span>
         <a href="http://www.trialsjournal.com/content/16/1/24">http://www.trialsjournal.com/content/16/1/24</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-014-0541-9</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">21</span>
               <span tagx="month">9</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">22</span>
               <span tagx="month">12</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">27</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Harris et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Extended-spectrum beta-lactamase</li>
         <li tagx="kwd">ESBL</li>
         <li tagx="kwd">Plasmid-AmpC</li>
         <li tagx="kwd">Therapy</li>
         <li tagx="kwd">Resistance</li>
         <li tagx="kwd">Beta-lactam/beta-lactamase inhibitor</li>
         <li tagx="kwd">Carbapenem</li>
         <li tagx="kwd">Clinical trial</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Gram-negative bacteria such as 
                  <i>Escherichia coli</i> or 
                  <i>Klebsiella</i> spp. frequently cause bloodstream infections. There has been a worldwide increase
                  in resistance in these species to antibiotics such as third generation cephalosporins,
                  largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated
                  AmpC enzymes. Carbapenems have been considered the most effective therapy for serious
                  infections caused by such resistant bacteria; however, increased use creates selection
                  pressure for carbapenem resistance, an emerging threat arising predominantly from
                  the dissemination of genes encoding carbapenemases. Recent retrospective data suggest
                  that beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam,
                  may be non-inferior to carbapenems for the treatment of bloodstream infection caused
                  by extended-spectrum beta-lactamase-producers, if susceptible 
                  <i>in vitro</i>. This study aims to test this hypothesis in an effort to define carbapenem-sparing
                  alternatives for these infections.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/Design</h3>
               </div>
               <p>The study will use a multicentre randomised controlled open-label non-inferiority
                  trial design comparing two treatments, meropenem (standard arm) and piperacillin-tazobactam
                  (carbapenem-sparing arm) in adult patients with bacteraemia caused by 
                  <i>E. coli</i> or 
                  <i>Klebsiella</i> spp. demonstrating non-susceptibility to third generation cephalosporins. Recruitment
                  is planned to occur in sites across three countries (Australia, New Zealand and Singapore).
                  A total sample size of 454 patients will be required to achieve 80% power to determine
                  non-inferiority with a margin of 5%. Once randomised, definitive treatment will be
                  for a minimum of 4 days, but up to 14 days with total duration determined by treating
                  clinicians. Data describing demographic information, antibiotic use, co-morbid conditions,
                  illness severity, source of infection and other risk factors will be collected. Vital
                  signs, white cell count, use of vasopressors and days to bacteraemia clearance will
                  be recorded up to day 7. The primary outcome measure will be mortality at 30 days,
                  with secondary outcomes including days to clinical and microbiological resolution,
                  microbiological failure or relapse, isolation of a multi-resistant organism or 
                  <i>Clostridium difficile</i> infection.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>The MERINO trial is registered under the Australian New Zealand Clinical Trials Register
                  (ANZCTR), reference number: 
                  <a href="ACTRN12613000532707">ACTRN12613000532707</a> (registered 13 May 2013) and the US National Institute of Health ClinicalTrials.gov
                  register, reference number: 
                  <a href="NCT02176122">NCT02176122</a> (registered 24 June 2014).
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>Bloodstream infections caused by Gram-negative bacteria such as 
         <i>Escherichia coli</i> or 
         <i>Klebsiella</i> spp. are commonly encountered in clinical practice and may be associated with significant
         mortality 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. These bacteria may also acquire genes encoding beta-lactamase enzymes that hydrolyse
         essential beta-lactam antibiotics, rendering such treatment ineffective. Isolates
         expressing extended-spectrum beta-lactamase (ESBL) or plasmid-mediated AmpC enzymes
         are increasingly encountered across the world, in both community- and hospital-onset
         infections 
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>. ESBL- or AmpC-producers are typically resistant to third generation cephalosporins
         such as ceftriaxone, but susceptible to carbapenems 
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. These bacteria are usually multi-resistant, as beta-lactamase genes are frequently
         co-located with other resistance mechanisms, leaving few treatment options. Bacteraemia
         caused by resistant Gram-negative bacteria may carry mortality in excess of those
         caused by susceptible strains 
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span>. Thus, defining optimal treatment regimens in these serious infections is of clinical
         importance. However, when selecting antimicrobial therapy, clinicians must consider
         both efficacy of the chosen agent and downstream risk such as selective pressure for
         further antimicrobial resistance.
      </p>
      <p>In observational studies that have been performed to evaluate antibiotic choices for
         ESBL-producing Enterobacteriaceae, no agent has been shown to significantly surpass
         carbapenems 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. However, widespread use of carbapenems may cause selection pressure for carbapenem
         resistance 
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>. Carbapenem-resistant Gram-negative bacteria present a great therapeutic challenge,
         with susceptibility often limited to ‘last-line’ antibiotics such as colistin or tigecycline.
         Some new beta-lactam antibiotics and beta-lactamase inhibitors, which are active against
         ESBL-, AmpC- and some carbapenemase-producing organisms, are in advanced clinical
         development 
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>. However, these antibiotics are likely to be expensive, are not yet on the market
         and may best be held in reserve for infections without therapeutic alternatives.
      </p>
      <p>The susceptibility of AmpC- and ESBL-producers to piperacillin-tazobactam is less
         predictable than carbapenems. By definition, ESBLs are inhibited by beta-lactamase
         inhibitors such as clavulanate or tazobactam 
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. However, 
         <i>E. coli</i> or 
         <i>Klebsiella</i> spp. may also produce multiple beta-lactamase types, some of which are resistant
         to inhibition by tazobactam and may not be evident by susceptibility testing alone.
         There have also been concerns that inoculum effects may overwhelm the activity of
         beta-lactamase inhibition in infections with a large bacterial burden 
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span>. Additionally, in some cases outer membrane protein loss may contribute to resistance
         to tazobactam 
         <span tagx="abbrgrp">
            <span tagx="abbr">14</span>
         </span>. By definition, AmpC enzymes are also not well inhibited by tazobactam 
         <span tagx="abbrgrp">
            <span tagx="abbr">15</span>
         </span>, and plasmid-mediated AmpC expression has been increasingly recognised as a cause
         of resistance to expanded spectrum cephalosporins in Enterobacteriaceae 
         <span tagx="abbrgrp">
            <span tagx="abbr">15</span>
         </span>. However, despite these concerns, approximately 50% or more of ceftriaxone non-susceptible
         
         <i>E. coli</i> or 
         <i>Klebsiella</i> spp. remain susceptible to piperacillin-tazobactam 
         <span tagx="abbrgrp">
            <span tagx="abbr">16</span>
         </span>. Yet, until recently, lack of published clinical experience with the use of beta-lactam/beta-lactamase
         inhibitor (BLBLI) agents for the treatment of ESBL-producers has limited their use.
         As a result, carbapenems have been perceived as a superior option. In recent years
         we have witnessed an alarming increase in the prevalence and global dissemination
         of carbapenem-resistant Gram-negative bacteria, largely driven by the spread of genes
         encoding carbapenemase enzymes, transmitted on highly mobile plasmids 
         <span tagx="abbrgrp">
            <span tagx="abbr">17</span>
         </span>. Thus, defining carbapenem-sparing treatment options for ESBL-producers has become
         imperative to reduce the selection pressure for carbapenem resistance 
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>.
      </p>
      <p>No randomised controlled trials (RCTs) have yet been performed comparing different
         treatment options for third generation cephalosporin-resistant Enterobacteriaceae.
         The largest observational study with an analysis by treatment outcome was published
         in 2012 by Rodriguez-Bano 
         <i>et al</i>. 
         <span tagx="abbrgrp">
            <span tagx="abbr">18</span>
         </span>. They performed a 
         <i>post hoc</i> analysis of six prospective cohorts of patients with bacteraemia due to ESBL-producing
         
         <i>E. coli</i>. Two non-mutually exclusive cohorts (empirical therapy and definitive therapy) were
         constructed and analysed separately. In both cohorts, carbapenems were not superior
         to BLBLI combinations, such as piperacillin-tazobactam. Specifically, in the definitive
         therapy cohort, mortality rates at 30 days were not significantly different - 9.3%
         for those who received a BLBLI and 16.7% for those who received a carbapenem (
         <i>P</i> &gt; 0.20) 
         <span tagx="abbrgrp">
            <span tagx="abbr">18</span>
         </span>. A subsequent meta-analysis of all published studies examining treatment options
         for bacteraemia caused by ESBL-producers also concluded that BLBLI agents were non-inferior
         to carbapenems for both definitive (relative risk (RR) 0.52, 95% confidence interval
         (CI) 0.23 to 1.13) or empirical therapy (RR 0.91, 95% CI 0.66 to 1.25) with regard
         to all-cause mortality 
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>. In contrast, mortality was lower with carbapenems when compared to non-BLBLI antibiotics
         (for example, quinolones) for both definitive (RR 0.65, 95% CI 0.47 to 0.91) and empirical
         treatment (RR 0.50, 95% CI 0.33 to 0.77).
      </p>
      <p>Both meropenem and piperacillin-tazobactam are antibiotics that have been widely used
         in clinical practice for many years. They have proven efficacy in a wide range of
         infectious syndromes, including severe sepsis, febrile neutropenia, ventilator-associated
         pneumonia and intra-abdominal sepsis. Both agents are licensed for the treatment of
         serious infections and are available for routine clinical use in generic formulations.
         A non-inferiority study design was selected because it is not ethically possible to
         conduct a placebo-controlled trial and piperacillin-tazobactam is not expected to
         be superior to meropenem with regard to the primary end-point. Instead, potential
         benefits relate to minimisation of ‘collateral damage’ in the form of selection for
         carbapenem-resistant Enterobacteriaceae.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods/Design</h2>
      </div>
      <p>The trial protocol was developed by the Gram-negative Working Group of the Australasian
         Society for Infectious Disease Clinical Research Network (ASID-CRN), in accordance
         with the CONSORT statement extension for ‘Non-inferiority and Equivalence Trials’
         
         <span tagx="abbrgrp">
            <span tagx="abbr">19</span>
         </span>.
      </p>
      <div id="">
         <div tagx="st">
            <h3>Hypothesis</h3>
         </div>
         <p>Our hypothesis is that piperacillin-tazobactam is non-inferior to meropenem for the
            definitive treatment of bloodstream infections due to third generation cephalosporin
            non-susceptible 
            <i>E. coli</i> or 
            <i>Klebsiella</i> spp.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study design</h3>
         </div>
         <p>The study design will be a multicentre randomised controlled non-inferiority open-label
            phase III trial. Both study drugs (meropenem and piperacillin-tazobactam) will be
            administered intravenously with standard dosing regimens. The study population will
            be all adult patients (18 years of age or older, or 21 years or older at Singapore
            sites) admitted to participating hospitals. Inclusion in the study will be determined
            by the presence of a bloodstream infection with 
            <i>E. coli</i> or 
            <i>Klebsiella</i> spp., as defined by at least one positive blood culture from a peripheral blood draw,
            where the isolate is confirmed to be third generation cephalosporin non-susceptible,
            but susceptible to piperacillin-tazobactam and meropenem by European Committee for
            Antimicrobial Susceptibility Testing (EUCAST) standards 
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Setting</h3>
         </div>
         <p>The trial will be conducted in several centres across Australia, New Zealand and Singapore
            (see Table 
            <span tagx="tblr">1</span>).
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 1</p>
            </div>
            <caption>
               <p>
                  <b>Proposed participating sites</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Country - State</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Facility</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>
                        <p>Australia - Queensland</p>
                     </td>
                     <td>
                        <p>Royal Brisbane and Women’s Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>St. Andrew’s War Memorial Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Brisbane Private Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Princess Alexandra Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>The Mater Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Australia - New South Wales</p>
                     </td>
                     <td>
                        <p>Westmead Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Wollongong Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Australia - Victoria</p>
                     </td>
                     <td>
                        <p>The Alfred Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Monash Medical Centre</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>The Austin Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Peter MacCallum Cancer Centre</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Dandenong Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Barwon Health</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Australia - Western Australia</p>
                     </td>
                     <td>
                        <p>Royal Perth Hospital</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>New Zealand</p>
                     </td>
                     <td>
                        <p>North Shore Hospital, Auckland</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Middlemore Hospital, Auckland</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Singapore</p>
                     </td>
                     <td>
                        <p>National University Hospital, Singapore</p>
                     </td>
                  </tr>
                  <tr>
                     <td></td>
                     <td>
                        <p>Tan Tock Seng Hospital, Singapore</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Intervention</h3>
         </div>
         <p>Meropenem 1 gram will be administered every 8 hours intravenously or piperacillin-tazobactam
            4.5 grams administered every 6 hours intravenously. Each dose will be given over 30
            minutes. The study drug is to be administered for a minimum of 4 days and can be given
            for as long as 14 days. The total duration of therapy will be determined by the treating
            clinician. Dose adjustment for renal impairment will be made according to the criteria
            in Table 
            <span tagx="tblr">2</span>. Blinding will not be performed as the two antibiotics have different dosing regimens.
            Follow-up will be for 30 days post enrolment. Other antimicrobials active against
            Gram-negative bacilli are excluded in the first 4 days after enrolment, except that
            trimethoprim/sulfamethoxazole may be continued as 
            <i>Pneumocystis</i> prophylaxis.
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 2</p>
            </div>
            <caption>
               <p>
                  <b>Dose adjustment for study antibiotics</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td></td>
                     <td>
                        <p>
                           <b>Meropenem</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Piperacillin-tazobactam</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>
                        <p>Creatinine clearance &gt; 50 mL/min</p>
                     </td>
                     <td>
                        <p>No change</p>
                     </td>
                     <td>
                        <p>No change</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Creatinine clearance 26 to 50 mL/min</p>
                     </td>
                     <td>
                        <p>1 g every 12 hours</p>
                     </td>
                     <td>
                        <p>4.5 g every 8 hours</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Creatinine clearance 10 to 25 mL/min</p>
                     </td>
                     <td>
                        <p>500 mg every 12 hours</p>
                     </td>
                     <td>
                        <p>4.5 g every 12 hours</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Creatinine clearance &lt; 10 mL/min</p>
                     </td>
                     <td>
                        <p>500 mg every 24 hours</p>
                     </td>
                     <td>
                        <p>4.5 g every 12 hours</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Haemodialysis</p>
                     </td>
                     <td>
                        <p>500 mg every 24 hours and 500 mg after each dialysis</p>
                     </td>
                     <td>
                        <p>2.25 g every 8 hours and an additional 0.75 g after each dialysis</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Peritoneal dialysis</p>
                     </td>
                     <td>
                        <p>500 mg every 24 hours</p>
                     </td>
                     <td>
                        <p>2.25 g every 8 hours</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Continuous-renal replacement therapy</p>
                     </td>
                     <td>
                        <p>1 g every 12 hours</p>
                     </td>
                     <td>
                        <p>4.5 g every 8 hours</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Primary objectives</h3>
         </div>
         <p> To compare the 30-day mortality post bloodstream infection in patients treated with
            piperacillin-tazobactam or meropenem
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Secondary objectives</h3>
         </div>
         <p> To compare the time to clinical and microbiologic resolution of infection for each
            regimen, defined as: number of days from randomisation to resolution of fever (temperature &gt; 38.0°C)
            and leucocytosis (white blood cell count &gt; 12 × 10
            <sup>9</sup>/L) PLUS sterilisation of blood cultures
         </p>
         <p> To compare the clinical and microbiologic success of each regimen at day 4 of the
            intervention, defined as survival PLUS resolution of fever and leucocytosis PLUS sterilisation
            of blood cultures. All of these criteria will be assessed on day 4, counted from the
            day of randomisation (day 1) in order to determine a rapid response from the trial
            drug
         </p>
         <p> To compare microbiologic resolution of infection, defined as sterility of blood cultures
            collected on or before day 4
         </p>
         <p> To compare the risk of relapse with each regimen, defined as growth of the same organism
            as in the original blood culture after the end of the period of study drug administration
            but before day 30
         </p>
         <p> To compare the risk of superinfection with a carbapenem or piperacillin-tazobactam-
            resistant organism or 
            <i>Clostridium difficile</i>, defined as growth of a meropenem or piperacillin-tazobactam-resistant organism from
            any clinical specimen collected from day 4 of study drug administration to day 30
            or a positive 
            <i>C. difficile</i> stool test (with the method of testing used according to local laboratory protocol).
            This endpoint is important since one of the purposes of establishing an alternative
            to carbapenem therapy is to reduce infections with resistant organisms or 
            <i>C. difficile</i>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Randomisation</h3>
         </div>
         <p>Patients will be randomly assigned to either meropenem or piperacillin-tazobactam
            in a 1:1 ratio according to a randomisation list prepared in advance for each recruiting
            site and stratification. Random sequence will be generated using random permuted blocks
            of unequal length. The randomisation process will be managed by the Queensland Clinical
            Trials &amp; Biostatistics Centre (QCTBC) of The University of Queensland, and generated
            using an online data management system (REDCap). Patients will be stratified into
            4 groups according to infecting species (
            <i>E. coli</i> or 
            <i>Klebsiella</i> spp.) and disease severity (according to a Pitt bacteraemia score 
            <span tagx="abbrgrp">
               <span tagx="abbr">21</span>
            </span> ≤ 4 or &gt; 4; and presumed site of infection from the urinary tract or elsewhere) (see
            Figure 
            <div tagx="figr">1</div>).
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 1</p>
            </div>
            <caption>
               <p>Patient stratification at enrolment. </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Patient stratification at enrolment.</b>
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Safety monitoring plan</h3>
         </div>
         <p>A Data Monitoring and Safety Board (DMSB) will be established, comprising two independent
            infectious disease physicians with statistical support provided to them by the QCTBC.
            An interim analysis - including both efficacy and safety endpoints - will be performed
            after the first 50 subjects have completed the 30-day study period. The trial statistician
            will provide details of safety outcomes and any significant differences in primary
            outcomes according to treatment arm to the DMSB. The stopping rule would be a statistically
            significant difference in primary outcomes between the two therapies.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Data entry and storage</h3>
         </div>
         <p>A clinical database using the REDCap trial data management system has been developed
            with a web hosting facility. Paper case report forms (CRFs) (Additional file 
            <div tagx="supplr">1</div>) will be completed and uploaded to the online system to collect all clinical and
            additional laboratory-related information (see Table 
            <span tagx="tblr">3</span>). To ensure accurate transcription of the CRF, double-data entry will be performed
            by a second independent researcher. Any discrepancies, missing data or errors will
            be clarified by discussion with the site principal investigator. To ensure validity,
            a proportion of CRFs will be checked by the local site investigators against clinical
            and laboratory records.
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 3</p>
            </div>
            <caption>
               <p>
                  <b>Data collection</b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td></td>
                     <td>
                        <p>
                           <b>Variables</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <div tagx="tfoot">
                  <p>
                     <i>Abbreviations</i>: 
                     <i>BP</i> blood pressure, 
                     <i>HR</i> heart rate, 
                     <i>RR</i> respiratory rate.
                  </p>
               </div>
               <tbody>
                  <tr>
                     <td>
                        <p>Demographic data</p>
                     </td>
                     <td>
                        <p>Age, gender, ethnicity, long-term residential care status, ward location</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Trial characteristics</p>
                     </td>
                     <td>
                        <p>Date of screening and enrolment, inclusion criteria and consent details, date and
                           time of randomization
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Co-morbidities and risk factors</p>
                     </td>
                     <td>
                        <p>Charlson score, co-morbid conditions, date and type of any surgery within 14 days,
                           use of cytotoxic chemotherapy, immune suppressive medication, radiotherapy, biological
                           agents (for example, monoclonal antibody therapy), presence of intravascular devices
                           or urinary catheters; use of ‘not for resuscitation’ order
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Infection parameters</p>
                     </td>
                     <td>
                        <p>Bacteraemia acquisition status (community, healthcare-associated or hospital-acquired
                           infection), presumed source of infection, ICU admission, Pitt bacteraemia score, Acute
                           Physiology and Chronic Health Evaluation (APACHE) II score (if in ICU)
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Antibiotic data</p>
                     </td>
                     <td>
                        <p>From 48 hours prior to blood culture collection and up to 30 days; dose/route/frequency
                           recorded
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Clinical observations</p>
                     </td>
                     <td>
                        <p>Daily vital signs, (highest temperature, HR, RR; lowest systolic BP), lowest arterial
                           pCO
                           <sub>2</sub> (if ventilated), white cell count, use of pressors; recorded days 1 to 7; patient
                           weight
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Microbiological data</p>
                     </td>
                     <td>
                        <p>Date and time of initial blood culture, full susceptibility profile, daily blood culture
                           results days 1 to 3; any further positive blood cultures and species identification/resistance
                           profile; other clinical sites growing 
                           <i>E coli</i> or 
                           <i>Klebsiella</i>, any multidrug-resistant organism or 
                           <i>C. difficile</i> identified up to 30 days
                        </p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Outcome data</p>
                     </td>
                     <td>
                        <p>Survival at 7 and 30 days post randomisation</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Date of death or discharge</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Length of hospital stay</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Days to clinical and microbiological resolution</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Clinical and microbiological success at day 4</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Microbiological resolution or relapse</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Protocol violations and adverse events</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>Reasons for study withdrawal</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Determination of sample size</h3>
         </div>
         <p>As no randomised clinical trial has yet been conducted in this particular field, the
            sample size estimation has been derived from the retrospective study of bloodstream
            infection caused by ESBL-producing 
            <i>E. coli</i> performed by Rodriguez-Bano 
            <i>et al</i>. 
            <span tagx="abbrgrp">
               <span tagx="abbr">7</span>
            </span>. The overall 30-day mortality in their study was 16.7% in those patients who received
            a carbapenem (our control group). We have conducted a series of simulations with possible
            variations in the observed rates between the two treatment groups. Considering a mortality
            rate of 17% in the control group (rounded from the 16.7% actually observed), and a
            non-inferiority margin of 5% difference in the 2 groups, we would need 280 patients
            in total to achieve 80% power with a 1-sided alpha level of 0.025. This allows for
            10% dropout. It is likely that mortality rates in observational cohorts may be greater
            than those in a trial with exclusion criteria. Therefore, if the observed mortality
            rate in the control group was 14% (3% lower than that seen in the observational cohort),
            then under the same assumptions, we would need 454 patients in total to achieve 80%
            power 
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
            </span>.
         </p>
         <p>Actual mortality is expected to be similar in our study population. We have performed
            a retrospective analysis of 92 bacteraemia episodes caused by ceftriaxone-resistant
            
            <i>E. coli</i> or 
            <i>Klebsiella</i> in Singapore (one of the trial sites) over a 12-month period until May 2013, examining
            patients that would fulfil the MERINO trial inclusion criteria. Average mortality
            at 30 days was 17.4% in patients given a carbapenem for definitive therapy. However,
            overall mortality for all treatment groups was lower at 8.7%, including those receiving
            BLBLIs (8.3%) 
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical and analytical plans</h3>
         </div>
         <p>The intention-to-treat (ITT) analysis approach, supported by the per-protocol approach,
            will be adopted to make inference on the possible non-inferiority of the treatment
            arm, compared to the control arm, in terms of 30-day mortality. The proportions of
            deaths (with 95% CIs) in the 2 study arms will be calculated. Logistic regression
            with ‘treatment group’ as the only covariate will be employed to draw inference on
            the possible non-inferiority of the intervention treatment compared to the control
            treatment. The odds ratio (with 95% CIs) will be calculated with the meropenem arm
            as the reference group. Appropriate parametric or non-parametric statistical techniques
            will be employed to analyse the data for secondary aims of the study. The Mann–Whitney
            
            <i>U</i>-test will be used to compare median number of days to clinical and microbiological
            resolution. Logistic regression will be used to compare odds ratios of achieving clinical
            and microbiological success and microbiological resolution at day 4, as well as the
            odds ratio for microbiological relapse and superinfection with a resistant organism
            between each treatment arm. All secondary analyses will be based on an ITT population.
         </p>
         <p>An analysis of primary and secondary endpoints as described above will be undertaken
            in a subgroup of ‘high risk’ patients defined by a likely source of infection other
            than the urinary tract or a Pitt bacteraemia score of &gt;4.
         </p>
         <p>Basic statistics in the study report will include information on missing values for
            all relevant study variables. A summary of baseline patient characteristics with totals
            and proportions (%) for categorical variables, and minimum, maximum, inter-quartile
            ranges and standard deviations for continuous variables will be presented. For continuous
            study variables, box plots and Kernel density plots will also be provided.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Protocol violations</h3>
         </div>
         <p>All protocol violations occurring after randomisation will be listed in the Clinical
            Study Report, tabulated by subject and recruitment site. The final assignment of participants
            to the per-protocol analysis population will be made at a blinded protocol violation
            review meeting prior to database lock.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Consent</h3>
         </div>
         <p>Potential study participants will be identified on the basis of positive blood cultures
            by liaison between the investigators and the clinical microbiologists. All patients
            who fulfill the microbiological inclusion criteria will be screened for eligibility
            using a standardised screening form (see Additional file 
            <div tagx="supplr">2</div>). The investigators will only approach the patient with the agreement of the treating
            team. As soon as practically possible after this discussion, the study team representative
            will approach the patient at the bedside to obtain consent. Typically this will be
            around 48 to 72 hours after the onset of clinical sepsis and the initial collection
            of blood cultures. For patients with cognitive impairment secondary to their illness
            (for example, intubation and ventilation, delirium), consent will be obtained from
            a legally appropriate representative (for example, spouse), where local regulatory
            requirements allow recruitment of cognitively-impaired persons to clinical trials.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study preparation and logistics</h3>
         </div>
         <p>The trial coordination centre comprises the project management team (THB, PH and DLP)
            at the University of Queensland Centre for Clinical Research in Brisbane. Site initiation
            and training will be conducted by PH, DLP and THB via web conferencing and/or site
            visits. Study sites will be contacted regularly via teleconference to discuss any
            issues and ensure consistent study practices across sites.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Laboratory studies</h3>
         </div>
         <p>All blood culture isolates will be made available to the central trial laboratory
            at the University of Queensland Centre for Clinical Research. Susceptibility testing,
            including minimum inhibitory concentrations for key antimicrobials, will be repeated
            in the central laboratory and interpreted according to EUCAST standards. Additional
            susceptibility testing for agents not tested at the recruiting site laboratories will
            also be performed. Phenotypic confirmation of ESBL or AmpC production will be performed
            using combination disc testing 
            <span tagx="abbrgrp">
               <span tagx="abbr">24</span>
            </span>. Beta-lactamase genes will be identified and characterized. Isolates will also be
            screened for carbapenemase genes and other key antimicrobial resistance determinants.
            Strain typing will be determined using methods such as semi-automated repetitive sequence-based
            PCR (rep-PCR) (DiversiLab; BioMérieux, Marcy l’Étoile, France) and multi-locus sequence
            typing (MLST). Isolates will also be available for whole genome sequencing.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Ethics</h3>
         </div>
         <p>The protocol has been given ethical approval by the Royal Brisbane and Women’s Hospital
            (ref: HREC/12/QRBW/440), the National Healthcare Group (NHG) Domain Specific Review
            Board (DSRB) in Singapore (NHG DSRB ref: 2013/00453) and the New Zealand Health and
            Disability Ethics Committee (Ref: 14/NTB/52).
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>The quality and extent of evidence to help define optimal treatment for many significant
         bacterial infections is surprisingly limited. This is especially true for the treatment
         of resistant Gram-negative bacteraemia, despite being a major issue in daily practice
         for clinicians across many specialties. In addition to laboratory data and expert
         opinion, current practice is almost entirely based on retrospective observational
         studies, usually conducted in single centres with relatively small numbers of patients.
         Such studies, though informative, are always prone to bias, thus weakening the strength
         of conclusions drawn for these analyses. To date, there have been no RCTs reported
         specifically comparing different treatment options for ceftriaxone-resistant Enterobacteriaceae.
      </p>
      <p>There is local support for the conduct of this study. This is highlighted by a recent
         online survey in which 122 infectious diseases physicians in Australia and New Zealand
         were asked to rank the research studies of greatest immediate clinical relevance -
         the proposed trial comparing meropenem and piperacillin-tazobactam was the highest
         ranked RCT in the field of antibiotic resistance in Gram-negative bacilli 
         <span tagx="abbrgrp">
            <span tagx="abbr">25</span>
         </span>.
      </p>
      <p>Antibiotic resistance is of tremendous public health importance and has been recently
         described as potentially the greatest current threat to human health 
         <span tagx="abbrgrp">
            <span tagx="abbr">26</span>
         </span>. The MERINO trial has potential significance for two reasons. Firstly, it addresses
         treatment of a common but serious antibiotic resistance issue that is associated with
         10 to 20% mortality 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">18</span>
         </span>. Secondly, proving that a carbapenem-sparing antibiotic regimen is non-inferior to
         a carbapenem will help encourage use of alternatives to carbapenems. Carbapenem resistance
         is the ‘end-game’ with respect to antibiotic resistance as it eliminates one of our
         most important antibiotic options and leaves few effective alternative treatments.
         Evidenced-based strategies to support the clinical management of resistant infections
         that consider both efficacy and the potential for ‘collateral damage’ of treatment
         options are therefore urgently needed.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>A pilot study based on this protocol has commenced recruitment in both Singapore and
         Australia in February 2014. The remaining study sites are scheduled to begin enrolment
         later during 2014 once local regulatory requirements have been completed. It is planned
         for the pilot phase to be extended to a definitive trial in early 2015. It is aimed
         that recruitment for the definitive study will be completed by late 2016. Data from
         the pilot phase will be included in the definitive study analysis.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>APACHE: Acute Physiology and Chronic Health Evaluation</p>
      <p>ASID: Australasian Society for Infectious Disease</p>
      <p>BLBLI: beta-lactam/beta-lactamase inhibitor</p>
      <p>CRF: Clinical record form</p>
      <p>CRN: Clinical Research Network</p>
      <p>DMSB: Data Monitoring and Safety Board</p>
      <p>DSRB: Domain Specific Review Board</p>
      <p>ESBL: extended-spectrum beta-lactamase</p>
      <p>EUCAST: European Committee for Antimicrobial Susceptibility Testing</p>
      <p>QCTBC: Queensland Clinical Trials and Biostatistics Unit</p>
      <p>ITT: intention-to-treat</p>
      <p>MLST: multi-locus sequence typing</p>
      <p>NHG: National Healthcare Group</p>
      <p>PCR: polymerase chain reaction</p>
      <p>QCTBC: Queensland Clinical Trials and Biostatistics Unit</p>
      <p>RCTs: randomised controlled trials</p>
      <p>RR: relative risk</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>SKP has acted as a consultant and speaker for Novartis and Amylin Pharmaceuticals,
         LLC. He has received grants in support of investigator and investigator initiated
         clinical studies from Merck, Novo Nordisk and Pfizer, Bristol Myer Squib, Amylin Pharmaceuticals
         and Hospira. SKP also received an infrastructure research grant from Therapeutic Innovations
         Australia. DLP has participated in advisory boards and received honoraria from AstraZeneca,
         Merck, Pfizer, Bayer, Cubist and Leo Pharmaceuticals. All other authors have no competing
         interests to declare.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>PH wrote the initial and final drafts of the manuscript. The concept for the study
         was proposed by AYP and DLP. The original protocol was developed by the Gram-negative
         Working Group of the ASID-CRN (AYP, JI, PRI, SM, AS, BAR, ESM, EA, THB and DLP) with
         additional input from JL and JAR. Statistical support was provided by SKP and PB.
         All authors have reviewed the final manuscript and approve its contents.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ information</h2>
      </div>
      <p>PH is an infectious disease physician and microbiologist and is currently undertaking
         a PhD with the Paterson group at UQCCR. AYP is an infectious disease physician and
         NHMRC Career Development Fellow. ESM is an infectious diseases physician and is the
         head of epidemiology at the Victorian Infectious Diseases Service. SM is a clinical
         academic infectious diseases and general medicine physician. AJS is an infectious
         diseases physician. PRI is an infectious diseases physician and microbiologist. BAR
         is an infectious disease physician. JL is a critical care specialist. JAR is a clinical
         pharmacist and NHMRC Research Fellow. JI is a physician and microbiologist and runs
         the NHMRC Centre for Research Excellence in Critical Infection in Sydney. EA is an
         infectious disease physician. SKP is a clinical trialist and biostatistician. PB is
         a statistician. THB is a registered nurse and is currently the Clinical Research Manager
         for the Paterson group at UQCCR. DLP is an infectious disease physician and microbiologist
         and chairs the ASID-CRN steering committee.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Additional files</h2>
      </div>
      <div tagx="suppl">
         <div tagx="title">
            <p>Additional file 1:</p>
         </div>
         <div tagx="text">
            <p>
               <b>MERINO Trial Clinical Record Form.</b>
            </p>
         </div>
         <div tagx="file">
            <p>Click here for file</p>
         </div>
      </div>
      <div tagx="suppl">
         <div tagx="title">
            <p>Additional file 2:</p>
         </div>
         <div tagx="text">
            <p>
               <b>MERINO Trials Initial Screening Form.</b>
            </p>
         </div>
         <div tagx="file">
            <p>Click here for file</p>
         </div>
      </div>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgments</h2>
            </div>
            <p>Funding for the trial has been received from the Australasian Society for Antimicrobials
               (ASA) and the International Society for Chemotherapy (ISC). We would like to acknowledge
               Anna Sartor (UQCCR) and Simon Forsyth (QCTBC) for assistance in setting up the REDCap
               database and all local site investigators for their involvement.
            </p>
            <p>On behalf of the Australasian Society for Infectious Diseases Clinical Research Network
               (ASID-CRN).
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>New method of classifying infections in critically ill patients</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cohen</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cristofaro</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Carlet</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Opal</span>
                  <span tagx="fnm">S</span>
               </li>
            </ul>
            <span tagx="source">Crit Care Med</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">32</span>
            <span tagx="issue">7</span>
            <span tagx="fpage">1510</span>
            <span tagx="lpage">26</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/01.CCM.0000129973.13104.2D</span>
                  <span tagx="pubid">15241096</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health
                  concern
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Pitout</span>
                  <span tagx="fnm">JD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Laupland</span>
                  <span tagx="fnm">KB</span>
               </li>
            </ul>
            <span tagx="source">Lancet Infect Dis</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">8</span>
            <span tagx="issue">3</span>
            <span tagx="fpage">159</span>
            <span tagx="lpage">66</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S1473-3099(08)70041-0</span>
                  <span tagx="pubid">18291338</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Extended-spectrum beta-lactamases: a clinical update</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Paterson</span>
                  <span tagx="fnm">DL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bonomo</span>
                  <span tagx="fnm">RA</span>
               </li>
            </ul>
            <span tagx="source">Clin Microbiol Rev</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">18</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">657</span>
            <span tagx="lpage">86</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/CMR.18.4.657-686.2005</span>
                  <span tagx="pubid">16223952</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Burden of antimicrobial resistance in European hospitals: excess mortality and length
                  of hospital stay associated with bloodstream infections due to Escherichia coli resistant
                  to third-generation cephalosporins
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">de Kraker</span>
                  <span tagx="fnm">MEA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wolkewitz</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Davey</span>
                  <span tagx="fnm">PG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Koller</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Berger</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Nagler</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Icket</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kalenic</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Horvatic</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Seifert</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kaasch</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Paniara</span>
                  <span tagx="fnm">O</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Argyropoulou</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bompola</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Smyth</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Skally</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Raglio</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dumpis</span>
                  <span tagx="fnm">U</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Melbarde Kelmere</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Borg</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Xuereb</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ghita</span>
                  <span tagx="fnm">MC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Noble</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kolman</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grabljevec</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Turner</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lansbury</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grundmann</span>
                  <span tagx="fnm">H</span>
               </li>
            </ul>
            <span tagx="source">J Antimicrob Chemother</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">66</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">398</span>
            <span tagx="lpage">407</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/jac/dkq412</span>
                  <span tagx="pubid">21106563</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production
                  of extended-spectrum beta-lactamases
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Paterson</span>
                  <span tagx="fnm">DL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ko</span>
                  <span tagx="fnm">WC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Von Gottberg</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mohapatra</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Casellas</span>
                  <span tagx="fnm">JM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Goossens</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mulazimoglu</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Trenholme</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klugman</span>
                  <span tagx="fnm">KP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bonomo</span>
                  <span tagx="fnm">RA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rice</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wagener</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McCormack</span>
                  <span tagx="fnm">JG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yu</span>
                  <span tagx="fnm">VL</span>
               </li>
            </ul>
            <span tagx="source">Clin Infect Dis</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">39</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">31</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1086/420816</span>
                  <span tagx="pubid">15206050</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to
                  Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review
                  and meta-analysis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Vardakas</span>
                  <span tagx="fnm">KZ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tansarli</span>
                  <span tagx="fnm">GS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rafailidis</span>
                  <span tagx="fnm">PI</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Falagas</span>
                  <span tagx="fnm">ME</span>
               </li>
            </ul>
            <span tagx="source">J Antimicrob Chemother</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">67</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">2793</span>
            <span tagx="lpage">803</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/jac/dks301</span>
                  <span tagx="pubid">22915465</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due
                  to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis
                  of prospective cohorts
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Rodriguez-Bano</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Navarro</span>
                  <span tagx="fnm">MD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Retamar</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Picon</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pascual</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Clin Infect Dis</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">54</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">167</span>
            <span tagx="lpage">74</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/cid/cir790</span>
                  <span tagx="pubid">22057701</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia
                  coli and Klebsiella spp. bacteremia. A multicentric cohort study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Peralta</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lamelo</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Alvarez-Garcia</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Velasco</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Delgado</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Horcajada</span>
                  <span tagx="fnm">JP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Montero</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Roiz</span>
                  <span tagx="fnm">MP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Farinas</span>
                  <span tagx="fnm">MC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Alonso</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Martinez</span>
                  <span tagx="fnm">LM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gutierrez-Macias</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Alava</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rodriguez</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fleites</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Navarro</span>
                  <span tagx="fnm">V</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sirvent</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Capdevila</span>
                  <span tagx="fnm">JA</span>
               </li>
            </ul>
            <span tagx="source">BMC Infect Dis</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">12</span>
            <span tagx="fpage">245</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/1471-2334-12-245</span>
                  <span tagx="pubid">23038999</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">McLaughlin</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Advincula</span>
                  <span tagx="fnm">MR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Malczynski</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qi</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bolon</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Scheetz</span>
                  <span tagx="fnm">MH</span>
               </li>
            </ul>
            <span tagx="source">Antimicrob Agents Chemother</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">57</span>
            <span tagx="issue">10</span>
            <span tagx="fpage">5131</span>
            <span tagx="lpage">3</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/AAC.00607-13</span>
                  <span tagx="pubid">23836188</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Gupta</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Limbago</span>
                  <span tagx="fnm">BM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Patel</span>
                  <span tagx="fnm">JB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kallen</span>
                  <span tagx="fnm">AJ</span>
               </li>
            </ul>
            <span tagx="source">Clin Infect Dis</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">53</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">60</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/cid/cir202</span>
                  <span tagx="pubid">21653305</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Infectious Diseases Society of A: 10 × ′20 progress-development of new drugs active
                  against gram-negative bacilli: an update from the Infectious Diseases Society of America
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Boucher</span>
                  <span tagx="fnm">HW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Talbot</span>
                  <span tagx="fnm">GH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Benjamin</span>
                  <span tagx="fnm">DK</span>
                  <div tagx="suf">Jr</div>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bradley</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guidos</span>
                  <span tagx="fnm">RJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jones</span>
                  <span tagx="fnm">RN</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Clin Infect Dis</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">56</span>
            <span tagx="issue">12</span>
            <span tagx="fpage">1685</span>
            <span tagx="lpage">94</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/cid/cit152</span>
                  <span tagx="pubid">23599308</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Drawz</span>
                  <span tagx="fnm">SM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Papp-Wallace</span>
                  <span tagx="fnm">KM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bonomo</span>
                  <span tagx="fnm">RA</span>
               </li>
            </ul>
            <span tagx="source">Antimicrob Agents Chemother</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">58</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">1835</span>
            <span tagx="lpage">46</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/AAC.00826-13</span>
                  <span tagx="pubid">24379206</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Killing of Escherichia coli by beta-lactams at different inocula</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Tam</span>
                  <span tagx="fnm">VH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ledesma</span>
                  <span tagx="fnm">KR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chang</span>
                  <span tagx="fnm">KT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">TY</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Quinn</span>
                  <span tagx="fnm">JP</span>
               </li>
            </ul>
            <span tagx="source">Diagn Microbiol Infect Dis</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">64</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">166</span>
            <span tagx="lpage">71</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.diagmicrobio.2009.01.018</span>
                  <span tagx="pubid">19304437</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane
                  protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical
                  isolate of Klebsiella pneumoniae
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Rice</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Carias</span>
                  <span tagx="fnm">LL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hujer</span>
                  <span tagx="fnm">AM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bonafede</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hutton</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hoyen</span>
                  <span tagx="fnm">C</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Antimicrob Agents Chemother</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">44</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">362</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/AAC.44.2.362-367.2000</span>
                  <span tagx="pubid">10639363</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>AmpC beta-lactamases</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jacoby</span>
                  <span tagx="fnm">GA</span>
               </li>
            </ul>
            <span tagx="source">Clin Microbiol Rev</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">22</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">161</span>
            <span tagx="lpage">82</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/CMR.00036-08</span>
                  <span tagx="pubid">19136439</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli
                  isolated from patients with intra-abdominal infections in the Asia-Pacific region
                  according to currently established susceptibility interpretive criteria
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chen</span>
                  <span tagx="fnm">YH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hsueh</span>
                  <span tagx="fnm">PR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Badal</span>
                  <span tagx="fnm">RE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hawser</span>
                  <span tagx="fnm">SP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hoban</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bouchillon</span>
                  <span tagx="fnm">SK</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Infect</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">62</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">280</span>
            <span tagx="lpage">91</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jinf.2011.02.009</span>
                  <span tagx="pubid">21382411</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving
                  crisis of global dimensions
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Tzouvelekis</span>
                  <span tagx="fnm">LS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Markogiannakis</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Psichogiou</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tassios</span>
                  <span tagx="fnm">PT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Daikos</span>
                  <span tagx="fnm">GL</span>
               </li>
            </ul>
            <span tagx="source">Clin Microbiol Rev</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">25</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">682</span>
            <span tagx="lpage">707</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1128/CMR.05035-11</span>
                  <span tagx="pubid">23034326</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo
                  de Estudio de Infeccion Hospitalaria G. beta-Lactam/beta-lactam inhibitor combinations
                  for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing
                  Escherichia coli: a post hoc analysis of prospective cohorts
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Rodriguez-Bano</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Navarro</span>
                  <span tagx="fnm">MD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Retamar</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Picon</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pascual</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Clin Infect Dis</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">54</span>
            <span tagx="issue">2</span>
            <span tagx="fpage">167</span>
            <span tagx="lpage">74</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1093/cid/cir790</span>
                  <span tagx="pubid">22057701</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT
                  2010 statement
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Piaggio</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Elbourne</span>
                  <span tagx="fnm">DR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pocock</span>
                  <span tagx="fnm">SJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Evans</span>
                  <span tagx="fnm">SJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Altman</span>
                  <span tagx="fnm">DG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Group</span>
                  <span tagx="fnm">C</span>
               </li>
            </ul>
            <span tagx="source">JAMA</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">308</span>
            <span tagx="issue">24</span>
            <span tagx="fpage">2594</span>
            <span tagx="lpage">604</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1001/jama.2012.87802</span>
                  <span tagx="pubid">23268518</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Breakpoint tables for interpretation of MICs and zone diameters version 4.0. Available
               from: 
               <a href="http://www.eucast.org">http://www.eucast.org</a>. Accessed 6
               <sup>th</sup> December 2014.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>International prospective study of Klebsiella pneumoniae bacteremia: implications
                  of extended-spectrum beta-lactamase production in nosocomial Infections
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Paterson</span>
                  <span tagx="fnm">DL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ko</span>
                  <span tagx="fnm">WC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Von Gottberg</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mohapatra</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Casellas</span>
                  <span tagx="fnm">JM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Goossens</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mulazimoglu</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Trenholme</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klugman</span>
                  <span tagx="fnm">KP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bonomo</span>
                  <span tagx="fnm">RA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rice</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wagener</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">McCormack</span>
                  <span tagx="fnm">JG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yu</span>
                  <span tagx="fnm">VL</span>
               </li>
            </ul>
            <span tagx="source">Ann Intern Med</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">140</span>
            <span tagx="issue">1</span>
            <span tagx="fpage">26</span>
            <span tagx="lpage">32</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.7326/0003-4819-140-1-200401060-00008</span>
                  <span tagx="pubid">14706969</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chow</span>
                  <span tagx="fnm">S-C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hansheng</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shao</span>
                  <span tagx="fnm">J</span>
               </li>
            </ul>
            <span tagx="source">Sample size calculations in clinical research</span>
            <div tagx="publisher">Chapman Hall, Boca Raton</div>
            <div tagx="edition">2</div>
            <span tagx="pubdate">2007</span>
         </div>
         <div tagx="bibl">
            <div tagx="note">Harris PNA, Mo Y, Jureen R, Chew J, Ali J, Paterson DL, Tambyah PA. Meropenem and
               piperacillin-tazobactam have comparable outcomes in treatment of bloodstream infections
               caused by extended spectrum beta-lactamase producing E.coli and Klebsiellae
               <b>.</b> Abstract number 486, IDWeek. Philadelphia, PA: 8 to 12 October 2014. Available from:
               
               <a href="https://idsa.confex.com/idsa/2014/webprogram/Paper46679.html">https://idsa.confex.com/idsa/2014/webprogram/Paper46679.html</a>. Accessed 12
               <sup>th</sup> Jan 2015.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">EUCAST guidelines for detection of resistance mechanisms and specific resistances
               of clinical and/or epidemiological importance. Available from: 
               <a href="http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf">http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_v1.0_20131211.pdf</a>. Accessed 26
               <sup>th</sup> Jan 2015.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Determining research priorities for clinician-initiated trials in infectious diseases</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Paterson</span>
                  <span tagx="fnm">DL</span>
               </li>
            </ul>
            <span tagx="source">Med J Aust</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">198</span>
            <span tagx="issue">5</span>
            <span tagx="fpage">270</span>
            <span tagx="lpage">2</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.5694/mja12.11703</span>
                  <span tagx="pubid">23496404</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The future of antibiotics and resistance</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Spellberg</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bartlett</span>
                  <span tagx="fnm">JG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gilbert</span>
                  <span tagx="fnm">DN</span>
               </li>
            </ul>
            <span tagx="source">N Engl J Med</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">368</span>
            <span tagx="issue">4</span>
            <span tagx="fpage">299</span>
            <span tagx="lpage">302</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1056/NEJMp1215093</span>
                  <span tagx="pubid">23343059</span>
               </div>
            </div>
         </div>
      </div>
   </div>
</html>